The AMCP Format public comment period facilitates an exchange of information between manufacturers and health care decision-makers to inform formulary and coverage decisions.
This JMCP article assesses the ability of the BBCIC distributed research network to serve as a potential resource for surveillance of biologics. The study provides recommendations to improve future comparative safety and effectiveness studies of biologics.
For two drugs with a branded product that had a large price increase, the market share of the related biosimilar or generic was higher among Medicaid MCOs not subject to preferred drug lists (PDLs) as compared to MCOs subject to PDLs and Medicaid FFS programs, according to a JMCP study.
The Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) was established to address anticipated needs for post-marketed evidence generation for novel biologics, their corresponding biosimilars and other related products.
AMCP comment letter on state legislation on medication synchronization.
AMCP comment letter on state legislation on interchangeable biologic products.
AMCP comment letter on state legislation on interchangeable biologic products.
AMCP comment letter on state legislation on interchangeable biologic products.
AMCP comment letter on state legislation on pharmacist substitution of biologics.
AMCP comments on state legislation on interchangeable biologics.
AMCP comments on state legislation on substitution of biologics.
AMCP comment letter on state legislation on interchangeable biologic products.
